NorthWest Biotherapeutics Inc (NWBO)

[biosectinvestor]

Agreements cover the ownership going into research like this. There is no issue.

NWBO owns DCVax-L, and it’s patens and IP, and commercial use, so they are a most important and key participant. Combinations, these agreements are common with universities and there may be a royalty payout or some similar payout upon licensing of the combination patent likely to UCLA and the others companies only likely to any extent not previously covered by agreements. For instance cognate and employees have been listed as inventors previously, but patents were assigned to NWBO. Revimmune, if they have a piece, then to the extent any technology they likely have is used, but it’s a broad patent, so probably not huge. UCLA and NWBO have a pre-existing agreement and the fact that Bosch and Powers are listed as co-inventors also works in favor of the company.

There may be payouts, but not for DCVax-L, for the additional combination value and probably a reasonable royalty. But obviously we’ll have to wait and see, but not a problem of any sort. These are common issues worked out frequently when companies partner with universities to develop a technology.